Pharmacological Study of Cefazolin Antibioprophylaxis in Liver Transplantation
NCT ID: NCT04280237
Last Updated: 2021-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2020-03-31
2020-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SURGICAL EXPERIENCE ON RENAL TRANSPLANT COMPLICATIONS
NCT05200949
Long-term Mortality Post Liver Transplantation in the Era of Modern Immunosuppression.
NCT06636409
Longitudinal Follow-up and Health-Related Outcomes in Liver Transplant Recipients and Living Donors
NCT07301853
Copeptin Serum Level in Liver Transplant Recipients
NCT03587623
Angiotensin II in Liver Transplantation
NCT04901169
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Due to the severe pharmacokinetics interactions caused by both prior hepatopathy and surgical techniques we suppose that Cefazolin blood levels are very different from those targeted for antibiotic prophylaxis.
This study aim to describe pharmacokinetics of Cefazolin during liver transplantation in order to adapt antibiotic prophylaxis strategy in case of unadapted measured levels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cefazolin in liver transplantation
Patient undergoing liver transplant surgery and receiving antibiotic prophylaxis with Cefazolin
Blood samples
Blood samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Blood samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient undergoing liver transplantation
* receiving Cefazolin as perioperative antibiotic prophylaxis to prevent surgical site infections
Exclusion Criteria
* legal protection or protected adults
* ongoing antibiotic treatment before liver transplantation
* patient inability to receive information or express opposition to the study.
* patient refusing participation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Charlotte TELLIER, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Tours
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Surgical intensive care unit, University Hospital, Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A00405-34
Identifier Type: OTHER
Identifier Source: secondary_id
RIPH3-RNI20/ProCeTH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.